NCT02791958Unknown2 期
Pharmacodynamic Equivalence Study of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy With the Reference Products Altace® 10 mg and Lipitor® 40 mg
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 528
- 试验地点
- 35
- 主要终点
- Difference in the adjusted mean 24-h systolic blood pressure results using ABPM between the baseline (week 0) and the final visit (week 8).
研究概览
简要总结
This study is to compare the pharmacodynamics of a Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) and the respective reference products, atorvastatin (Lipitor®) 40 mg and ramipril (Altace®) 10 mg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged ≥18 and <75 years.
- •Patients with Stage 1 (SBP/DBP: 140-159/90-99 mmHg) or Stage 2 (SBP/DBP: ≥160/≥100 mmHg) hypertension, either untreated or after a wash out period.
- •Patients with an LDL cholesterol level of ≥100 mg/dL and, either untreated or after the wash out period.
- •Patients untreated with BP lowering and / or lipid lowering medication
- •Patients treated with BP lowering and / or lipid lowering medication can be included if the medication can be safely withdrawn as per physician's judgment.
- •Provide written informed consent.
排除标准
- •Patients with a BMI of > 35
- •SBP < 140 mmHg and DBP < 90 mmHg
- •Severe hypertension defined as SBP > 180 mmHg and Diastolic Blood Pressure (DBP) > 110 mmHg
- •LDL cholesterol level of <100 mg/dL, either untreated or after the wash out period.
- •Serum triglyceride concentration ≥400 mg/dL, either untreated or after the wash out period.
- •Patients with a medical condition requiring the chronic pharmacological treatments listed below:
- •Cytochrome P450 3A4 (CYP3A4) inhibitors (eg itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone).
- •Non-steroidal anti-inflammatory drugs (NSAIDs).
- •K-sparing diuretics.
- •Amiodarone and verapamil.
- •Oral anticoagulants (eg, warfarin).
- •Steroids.
- •Gemfibrozil.
- •Potassium supplements.
- •Cyclosporine.
- •Rifampicin.
- •Evidence of any known clinically significant chronic disease
- •Patients with renal impairment with Creatinine Clearance (CrCl) < 40 mL/ min/ 1.73 m2
- •Creatine phosphokinase (CPK) ≥5 x the upper limit of normal (ULN).
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 x ULN.
- •Total bilirubin ≥1.5 x ULN
- •Medical history or evidence of drug or alcohol abuse.
- •Medical history of gastrointestinal bleeding or gastroduodenal ulcer.
- •Presence of secondary dyslipidemia.
- •For patients on antihypertensive and/ or cholesterol lowering medication impossibility to withdraw it safely as per physician's judgment
- •Previous coronary artery bypass graft (CABG).
- •Previous percutaneous transluminal coronary angioplasty (PTCA) with a drug-eluting stent.
- •Presence of severe congestive heart failure (New York Heart Classification (NYHC) III IV).
- •Prior history of stroke, Transient Ischemic Attack (TIA), Myocardial Infarction (MI), and cardiomyopathy with systolic dysfunction (prior documented Left Ventricular Ejection Fraction (LVEF) < 40%)
- •Aspirin induced asthma
- •Previous intolerance and/or hypersensitivity to ACE inhibitors, statins and/or salicylates.
- •Presence of unstable angina.
- •Lab values other than specified out of the central laboratory normal range considered clinically significant.
- •Patients and their partners not using effective contraception methods (i.e. intra uterine device (IUD) and condom or diaphragm with spermicide and condom) during the study and for at least one month thereafter, oral contraceptives are allowed.
- •Pregnant, lactating, breastfeeding, or intends to become pregnant during the course of the study (females only). All women must have a negative urine pregnancy test at the Screening Visit, be surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or have a postmenopausal status (no menses) for at least one year.
- •Presence of mental illness limiting the capacity for self-care.
- •Presence of major systemic illnesses: renal disease, liver disease, neurological or psychiatric disease.
- •Participation, in the 30 days preceding enrolment into the study, in any other clinical study in which investigational or marketed drugs were employed.
- •Any other medical condition that in the investigators opinion may interfere with the study procedures and/or evaluations.
研究组 & 干预措施
CV Fixed Dose Combination Pill AAR
Experimental
Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg).
干预措施: Cardiovascular Fixed Dose Combination Pill AAR (Drug)
Atorvastatin
Active Comparator
Atorvastatin 40 mg (Lipitor®).
干预措施: Atorvastatin 40 mg (Drug)
Ramipril
Active Comparator
Ramipril 10 mg (Altace®).
干预措施: Ramipril 10 mg (Drug)
结局指标
主要结局
Difference in the adjusted mean 24-h systolic blood pressure results using ABPM between the baseline (week 0) and the final visit (week 8).
时间窗: Measures at baseline visit (week 0) and final visit (week 8).
Difference in LDL cholesterol levels between the baseline (week 4) and the final visit (week 8).
时间窗: Measures at baseline visit (week 4) and final visit (week 8).
次要结局
- Difference in the adjusted mean 24-h diastolic blood pressure results (using ABPM) between the basal and the final visits.(Measures at baseline visit (week 0) and final visit (week 8).)
- Difference in the adjusted mean 24-h mean arterial pressure results (using ABPM) between the basal and the final visits.(Measures at baseline visit (week 0) and final visit (week 8).)
- Difference in the adjusted mean 24-h heart rate results (using ABPM) between the basal and the final visits.(Measures at baseline visit (week 0) and final visit (week 8).)
- Difference in Very Low-Density Lipoprotein (VLDL) cholesterol levels between the basal and the final visits.(Measures at baseline visit (week 0) and final visit (week 8).)
- Difference in HDL cholesterol levels between the basal and the final visits.(Measures at baseline visit (week 0) and final visit (week 8).)
- Difference in total cholesterol levels between the basal and the final visits.(Measures at baseline visit (week 0) and final visit (week 8).)
- Difference in triglyceride levels between the basal and the final visits.(Measures at baseline visit (week 0) and final visit (week 8).)
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability](Through study completion, an average of 3 months.)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of Ramipril 10 mg Capsules Under Fed ConditionsHypertensionNCT00702260Roxane Laboratories39
已完成
1 期
Comparison to assess similarity of a new medicine (Neopharmed Gentili S.r.l.) versus the simultaneous administration of Triatec® (Sanofi-Aventis) and Congescor® (Daiichi Sankyo)ot applicable, this is s Bioequivalence studyISRCTN17559039eopharmed Gentili S.r.l.36
已完成
1 期
Bioequivalence study of a new capsule containing ramipril 10 mg and bisoprolol fumarate 5 mg (Neopharmed Gentili S.r.l.) versus the simultaneous administration of ramipril 10 mg tablets ( Triatec®, Sanofi-Aventis) and bisoprolol fumarate 5 mg film coated tablets (Congescor®, Daiichi Sankyo) in healthy male and female volunteers under fasting conditionsot applicableISRCTN35244287eopharmed Gentili S.r.l.36
已完成
1 期
Study to assess whether the amount of drugs that reach the blood circulation, are metabolised and eliminated after the intake by healthy volunteers under fasting conditions of one new capsule containing both ramipril and furosemide, is the same as after the intake of two separate tablets Triatec (ramipril) and Lasix (furosemide)Bioequivalence study in healthy volunteersISRCTN64925094eopharmed Gentili S.p.A.48
已完成
不适用
Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting ConditionsHypertensionNCT00702091Roxane Laboratories39